Login to Your Account

J&J Pits Medivir's TMC435 Against Vertex's Incivek

By Cormac Sheridan
Staff Writer

Wednesday, March 14, 2012
Johnson & Johnson, in a sense, is going head to head with itself by pitting its investigational protease inhibitor, TMC435, which it in-licensed from Medivir AB, against telaprevir, the hepatitis C virus (HCV) drug it markets as Incivo in Europe, Latin America, India and several other regions, in a Phase III trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription